MOTS-C vs SS-31

What Are MOTS-C and SS-31?

MOTS-C (Mitochondrial ORF of the 12S rRNA Type-C) is a Mitochondrial-derived peptide, metabolic regulator. Encoded by the 12S rRNA region of the mitochondrial genome; naturally produced in response to stress, exercise, and aging. It is researched for improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility.

SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do MOTS-C and SS-31 Work Differently?

MOTS-C mechanism: Translocates to the nucleus where it regulates gene expression through the Folate-AICAR-AMPK pathway. Activates antioxidant response elements (ARE) and interacts with NRF2 transcription factor to enhance cellular stress resistance. Improves insulin sensitivity and glucose metabolism through AMPK pathway activation, essentially mimicking exercise at the molecular level.

SS-31 mechanism: Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactive oxygen species production, increases ATP generation, and prevents apoptosis through mitochondrial outer membrane stabilization.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

MOTS-C: 5-10 mg per week administered 2-3 times weekly via subcutaneous injection. Half-life: not established in humans. Cycle: 8-12 weeks with 8-12 week breaks.

SS-31: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Half-life: approximately 20-30 minutes. Cycle: 12-48 weeks in clinical trials.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

MOTS-C benefits: improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility.

SS-31 benefits: improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

MOTS-C: Generally well-tolerated. Mild injection site reactions and transient digestive disturbances at higher doses. CB4211 analog showed good tolerability in a 4-week human trial.

SS-31: Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.

Can You Stack MOTS-C and SS-31 Together?

Many researchers combine MOTS-C and SS-31 in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

Pairs with SS-31 (another mitochondrial-targeting peptide) for enhanced mitochondrial biogenesis, and with 5-Amino-1MQ for comprehensive metabolic optimization. See our stacking guide for general principles.

Which Is Better: MOTS-C or SS-31?

There is no universal answer. MOTS-C may be preferable for researchers focused on improved insulin sensitivity, while SS-31 is stronger for improved muscle strength.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: MOTS-C | SS-31.

Frequently Asked Questions